Undetectable BCR–ABL transcripts in patients with chronic myeloid leukemia (CML) should
not be regarded as indicative of a cure, due to the sensitivity limit of current real-time …

The BCR-ABL1 translocation is a hallmark of chronic myeloid leukemia. Because patients
treated with imatinib and other tyrosine kinase inhibitors achieve lower levels of detectable …

Molecular monitoring of the BCR-ABL transcript in chronic myelogenous leukemia (CML)
using quantitative RT-PCR provides clinicians with important diagnostic and prognostic …

In patients with chronic myeloid leukemia, the use of real-time quantitative reverse
transcription-polymerase chain reaction (qRT-PCR) for measuring BCR-ABL1 transcripts …

Real-time quantitative PCR (RT-qPCR) is the gold standard to quantify the BCR-ABL1
transcript for molecular response monitoring in chronic myeloid leukemia (CML) patients …

BACKGROUND AND OBJECTIVES: The limited value of qualitative reverse transcription
polymerase chain-reaction (RT-PCR) for monitoring chronic myeloid leukemia (CML) …

Objective Molecular monitoring of treatment response in patients with chronic myelogenous
leukemia is performed using the Europe Against Cancer (EAC) qPCR assay using the …

Serial quantification of BCR-ABL1 messenger RNA (mRNA) is an important therapeutic
indicator for patients with chronic myeloid leukemia, but historically, there has been …

Molecular monitoring plays an essential role in the clinical management of chronic myeloid
leukemia (CML) patients, and now guides clinical decision making. Quantitative reverse …

Increasing numbers of patients with chronic myeloid leukaemia (CML) treated with tyrosine
kinase inhibitors achieve undetectable levels of BCR‐ABL mRNA using sensitive …